Cover Image
市場調查報告書

牙周病:開發中產品分析

Periodontitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 276008
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
牙周病:開發中產品分析 Periodontitis - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 60 Pages
簡介

牙周病是造成軟組織受損的牙齦感染,會破壞支撐牙齒的骨頭。常見的症狀有牙齦腫、牙齦呈鮮紅色/淡紫色、口臭、齒間呈現鮮紅色/淡紫色等。危險因子有牙齦炎、遺傳、糖尿病、年齡、藥物濫用、免疫力低落等。

本報告提供牙周病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息新聞稿等資訊。

簡介

  • 調查範圍

牙周病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

牙周病:企業開發中的治療藥

牙周病:大學/機關研究中的治療藥

牙周病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

牙周病:企業開發中的產品

牙周病:大學/機關研究中的產品

牙周病的治療藥的開發企業

  • Amyndas Pharmaceuticals LLC
  • C3 Jian, Inc
  • CSL Limited
  • Ensol Biosciences Inc.
  • Enzo Biochem, Inc.
  • Geistlich Pharma AG
  • 科研製藥
  • TGV-Laboratories

牙周病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

牙周病:暫停中的計劃

牙周病:開發中止的產品

牙周病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8418IDB

Summary

Global Markets Direct's, 'Periodontitis - Pipeline Review, H2 2016', provides an overview of the Periodontitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Periodontitis
  • The report reviews pipeline therapeutics for Periodontitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Periodontitis therapeutics and enlists all their major and minor projects
  • The report assesses Periodontitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Periodontitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Periodontitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Periodontitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Periodontitis Overview
  • Therapeutics Development
    • Pipeline Products for Periodontitis - Overview
    • Pipeline Products for Periodontitis - Comparative Analysis
  • Periodontitis - Therapeutics under Development by Companies
  • Periodontitis - Therapeutics under Investigation by Universities/Institutes
  • Periodontitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Periodontitis - Products under Development by Companies
  • Periodontitis - Products under Investigation by Universities/Institutes
  • Periodontitis - Companies Involved in Therapeutics Development
    • Amyndas Pharmaceuticals LLC
    • C3 Jian, Inc
    • CSL Limited
    • Ensol Biosciences Inc.
    • Enzo Biochem, Inc.
    • Geistlich Pharma AG
    • Kaken Pharmaceutical Co., Ltd.
    • TGV-Laboratories
  • Periodontitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AMY-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize C5aR for Periodontitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Enzo-D58 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hesed-3000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PODCRC-OHS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Periodontitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Periodontitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • taurolidine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trafermin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Periodontitis - Dormant Projects
  • Periodontitis - Discontinued Products
  • Periodontitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis
      • Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis
      • Oct 01, 2015: Kaken Submits a New Drug Application for "KCB-1D", Medicinal Product for Periodontal Regeneration
      • May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment
      • Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D
      • Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Periodontitis, H2 2016
  • Number of Products under Development for Periodontitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Periodontitis - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016
  • Periodontitis - Pipeline by C3 Jian, Inc, H2 2016
  • Periodontitis - Pipeline by CSL Limited, H2 2016
  • Periodontitis - Pipeline by Ensol Biosciences Inc., H2 2016
  • Periodontitis - Pipeline by Enzo Biochem, Inc., H2 2016
  • Periodontitis - Pipeline by Geistlich Pharma AG, H2 2016
  • Periodontitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016
  • Periodontitis - Pipeline by TGV-Laboratories, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Periodontitis - Dormant Projects, H2 2016
  • Periodontitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Periodontitis, H2 2016
  • Number of Products under Development for Periodontitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top